Idiopathic dwarfism Idiopathic dwarfism is one of the most common causes of dwarfism in children. It is defined as short stature below 2 SD or below the 3rd percentile of the average height of people of the same race, age, and sex, and excluding some other disorders such as hyposecretion of growth hormone, congenital ovarian hypoplasia, precocious puberty, chronic organic disease, and hypothyroidism.
Treatment of Idiopathic Dwarfism The FDA approval of growth hormone for the treatment of idiopathic dwarfism was based on 2 randomized, multicenter clinical studies involving 300 children with idiopathic dwarfism. After growth hormone treatment, there was a statistical difference in height growth.
These 2 clinical trials confirmed that growth hormone treatment for idiopathic dwarfism is indeed effective, and many clinical trials have demonstrated that growth hormone treatment for idiopathic dwarfism does not accelerate the child’s bone age or cause early epiphyseal closure while height growth is occurring. The current recommended dose of growth hormone for idiopathic dwarfism is 0.1~0.2 IU/kg/day, but because the cause of idiopathic dwarfism is unknown, there are individual differences in treatment effects.
It is believed that with the continuous development of technology and further research on idiopathic dwarfism, more and more causes will be discovered, which will improve the treatment of idiopathic dwarfism.